重新评估格列本脲(优降糖)最大剂量的初步研究  

RE EVALUATION OF THE MAXIMAL DOSE OF GLIBENCLAMIDE RECOMMENDED IN NIDDM PATIENTS

作　　者：李焱[1] 钟光恕[1] 程桦[1] 黎锋[1] 傅祖植[1] 

机构地区：[1]广州中山医科大学孙逸仙纪念医院内分泌科

出　　处：《中华内分泌代谢杂志》1997年第1期30-33,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：为研究不同格列本脲（优降糖）剂量对ＮＩＤＤＭ糖代谢及β细胞功能的影响。１７例ＮＩＤＤＭ患者，格列本脲由１０ｍｇ／天增至１５ｍｇ／天。治疗三个月后，血清格列本脲浓度升高，但空腹血糖和Ｃ肽，胰升糖素刺激后６分钟Ｃ肽，糖基化血红蛋白，胰岛素敏感指数均无改变，总胆固醇和甘油三酯亦无变化，高密度脂蛋白胆固醇轻度下降。提示有必要重新评估格列本脲的最大有效剂量。Seventeen non insulin dependent diabetic females had been treated with glibenclamide 10mg/day for more than one year, but fasting serum glucose was higher than 8 mmol/L. After the dose of glibenclamide was increased up to 15mg/day for three months, the serum concentration of glibenclamide increased from 21ng/ml to 57ng/ml (P<0.05); however, there were no significant changes in fasting serum glucose, glycosylated haemoglobin, insulin sensitivity index, fasting and glucagon stimulating serum c peptide. Neither was there a significant change in the decrement percentage of continuing fasting glucose after 7.5mg glibenclamide orally. The serum high density lipoprotein cholesterol decreased from 1.35±0.36mmol/L to 1.13±0.27mmol/L (P<0.05), but triglyceride and total cholesterol did not change significantly. These data suggest that the treatment with glibenclamide in a daily dose of more than 10mg could not improve the glucose metabolic control, and therefore it is worth while re evaluating the recommended maximal dose of glibenclamide.

关 键 词：NIDDM 糖尿病 格列本脲 剂量 

分 类 号：R587.105[医药卫生—内分泌]